News Wire ~ 3rd Party Press Release

167 POSTS 0 COMMENTS
Drone Concept

Research Tests Speed of Drones in Responding to Medical Emergency Scenarios

Research suggests that, in certain cases, drones could quickly deliver life-saving interventions during city’s peak rush hour.
Liquid in Dosing Cup

Use of Antihistamines for Anaphylaxis Symptoms Linked with Delay in Seeking Emergency Treatment

A majority of families whose children were hospitalized for anaphylaxis turned first to antihistamines, which can’t prevent allergic reaction from becoming fatal.
Wheat

New Treatment May Reverse Celiac Disease

New technology may be applicable to other autoimmune diseases and allergies.
Aptar Pharma’s BDS Device

Bryn Pharma Partners with Aptar Pharma for Nasal Epinephrine Treatment

Bryn’s epinephrine nasal spray provides two doses in one portable device.
EpiPen Recall

Pfizer Canada Recall: Some EpiPen and EpiPen Jr Auto-Injectors May Be Difficult to Remove...

Consumers and pharmacists in Canada should check that devices can be removed from their carrier tubes with ease.
FAF Stage

Food Allergy Fund Summit: November 14 – Washington DC

Join us for a day of learning, raising awareness, and funding research on November 14th at the Newseum in Washington, DC.
Nose

Bryn Pharma Completes Dosing in Pivotal Clinical Trial Designed to Support US Approval of...

Nasal Spray Product is Disruptive Innovation for People at Risk of Anaphylaxis.
Viaskin Peanut

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment...

If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.

Mylan to Pay $30 Million for Disclosure and Accounting Failure Relating to EpiPen

Mylan agreed to pay $30 million to settle charges they overcharged Medicaid hundreds of millions of dollars for EpiPen.
AAAAI Logo + Palforzia

AAAAI Addresses What Patients and Their Families Need to Know About Oral Immunotherapy (OIT)

As the FDA moves closer to approving the first food allergy treatment, the AAAAI seeks to help patients and their families understand the realities surrounding OIT.